2026-10-18T23:47:46Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/142242026-10-18T20:43:14Zopenairedrivercom_ebyu_10000col_ebyu_10001

Pharmacokinetics of cefquinome in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injectionsUney, K.Altan, F.Cetin, G.Aboubakr, M.Dik, B.Sayın, Z.Er, A.Elmas, M.cefquinomepharmacokineticsred-eared slider turtleAnimalsAnti-Bacterial AgentsCephalosporinsHalf-LifeInjections, IntramuscularInjections, IntravenousTurtlesantiinfective agentcephalosporin derivativeanimal experimentarea under the curveArticlebirdclinical effectivenessdrug absorptiondrug bioavailabilitydrug blood leveldrug mechanismelimination half-lifehigh performance liquid chromatographymammalmaximum plasma concentrationnonhumanplasma clearancepriority journalsingle drug dosetime to maximum plasma concentrationThe purpose of this study was to evaluate the pharmacokinetics of cefquinome (CFQ) following single intravenous (IV) or intramuscular (IM) injections of 2 mg/kg body weight in red-eared slider turtles. Plasma concentrations of CFQ were determined by high-performance liquid chromatography and analyzed using noncompartmental methods. The pharmacokinetic parameters following IV injection were as follows: elimination half-life (t1/2λz) 21.73 ± 4.95 hr, volume of distribution at steady-state (Vdss) 0.37 ± 0.11 L/kg, area under the plasma concentration–time curve (AUC0–∞) 163 ± 32 μg hr−1 ml−1, and total body clearance (ClT) 12.66 ± 2.51 ml hr−1 kg−1. The pharmacokinetic parameters after IM injection were as follows: peak plasma concentration (Cmax) 3.94 ± 0.84 μg/ml, time to peak concentration (Tmax) 3 hr, t1/2λz 26.90 ± 4.33 hr, and AUC0–∞ 145 ± 48 μg hr−1 ml−1. The bioavailability after IM injection was 88%. Data suggest that CFQ has a favorable pharmacokinetic profile with a long half-life and a high bioavailability in red-eared slider turtles. Further studies are needed to establish a multiple dosage regimen and evaluate clinical efficacy. © 2017 John Wiley & Sons LtdBlackwell Publishing Ltd2018Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/14224https://doi.org/10.1111/jvp.124480140-7783enJournal of Veterinary Pharmacology and Therapeuticsinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/14224